The California product liability attorneys at Cutter Law P.C. are investigating claims involving Onglyza (saxagliptin), a blood sugar-lowering medication for treating Type 2 diabetes.
If you or a loved one was injured by Onglyza, you may be eligible to file an Onglyza lawsuit. We encourage you to contact our legal team immediately to set up a free case evaluation.
Approved by the U.S. Food and Drug Administration (FDA) in 2009, Onglyza is a prescription medication that treats diabetes by mimicking hormones that stimulate the pancreas to produce more insulin. The oral medication, manufactured by AstraZeneca and Bristol-Myers Squibb, quickly grew in popularity because of its ability to effectively control blood sugar without causing weight gain like other diabetes medications.
Onglyza Side Effects
Onglyza and other drugs in the “incretin mimetics” class have been linked to a potential risk of pancreatitis, pancreatic cancer, heart failure and thyroid cancer.
Additional side effects may include:
- Hypersensitivity reactions (anaphylaxis, angioedema, exfoliative skin conditions)
- Hypoglycemia (dangerously low blood sugar levels)
- Skin reactions (thrombocytopenic purpura)
Onglyza Linked To Heart Failure
In February 2014, the FDA issued a safety alert after a study published in the New England Journal of Medicine linked Onglyza to a 27 percent increased risk of heart failure.
Study Links Incretin Mimetic Drugs To Pancreatic Cancer
In March 2013, the Diabetes Journal published a study that found alarming evidence linking incretin mimetic drugs such as Onglyza to pancreatitis and pancreatic cancer.
In the study, researchers performed autopsies on people with Type 2 diabetes who had taken incretin mimetic drugs and died of unspecified causes. The findings demonstrated a 40 percent increased pancreatic mass in patients who were on incretin mimetic medication, a six-fold increase in beta-cell mass, proliferation of precancerous cells and adenomas (benign tumors made of glandular tissue that can become malignant).
Onglyza And Thyroid Cancer
Researchers found that Victoza, another incretin mimetic drug that shares close similarities with Onglyza, caused malignant thyroid cancer and acute pancreatitis in rodents who were given a “clinically relevant” dose of the drug. The FDA published a safety warning in June 2011 about the risk of thyroid cancer from Victoza. Additionally, they have received numerous reports of patients diagnosed with thyroid cancer after taking other forms of incretin mimetics, including Januvia (sitagliptin) and Byetta (exenatide).
Free Consultation: Contact Us Today
If you or a loved one has taken Onglyza and experienced severe side effects, you may be entitled to compensation for your pain and suffering.
As a contingency-based firm, there is never an upfront cost to you, and we get paid only if we win a monetary recovery. Give us a call toll free at 916-461-8492 or request a free case evaluation online.